---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-028414"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:25:21.487583+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics shareholders approve all proposals at 2022 annual meeting

## Summary
- Re-elected David E. Jorden, C. Eric Winzer, Scott M. Pittman, and Paul D. Mintz as directors.
- Ratified Marcum LLP as independent auditor for FY2022 with 27,697,944 votes for, 1,074 against.
- Advisory vote on executive compensation approved with 26,692,397 for, 5,370 against, 5,000 abstain.
- Advisory vote on frequency set to every three years based on 23,767,794 votes for three years.
- Approved amendment to 2016 Omnibus Incentive Compensation Plan with 26,188,825 for, 7,988 against.

## SEC filing metadata
- accession: 0001437749-22-028414
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/aurx20221202b_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-028414
- JSON: https://secwatch.observer/filing/0001437749-22-028414.json
- Plain text: https://secwatch.observer/filing/0001437749-22-028414.txt

## Key facts
- Shareholder Votes
  Nuo Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2022-12-02 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2022-12-02
  source text: One Year Two Years Three Years Abstain 4. To approve, on an advisory basis, the frequency of the advisory vote on executive compensation 2,389,764 37,874 23,767,794 507,335
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm
- Shareholder Votes
  Nuo Therapeutics, Inc. shareholders approved Ratification of the appointment of Marcum LLP as independent registered public accounting firm for fiscal year 2022 at the 2022-12-02 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2022-12-02
  source text: For Withheld Abstain 2. To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 27,697,944 1,074 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm
- Shareholder Votes
  Nuo Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2022-12-02 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2022-12-02
  source text: For Withheld Abstain 3. To approve, on an advisory basis, the compensation of the Company's named executive officers 26,692,397 5,370 5,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm
- Shareholder Votes
  Nuo Therapeutics, Inc. shareholders approved Election of four directors to serve on the Board of Directors at the 2022-12-02 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2022-12-02
  source text: 1. Election of Directors For Withheld Broker Non-Votes David E. Jorden 26,699,444 3,323 996,251 C. Eric Winzer 26,198,490 504,277 996,251 Scott M. Pittman 26,199,444 503,323 996,251 Paul D. Mintz 26,199,444 503,323 996,251
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm
- Shareholder Votes
  Nuo Therapeutics, Inc. shareholders approved Ratification and approval of the 2016 Omnibus Incentive Compensation Plan, as amended at the 2022-12-02 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2022-12-02
  source text: For Withheld Abstain 5. To ratify and approve the Company's 2016 Omnibus Incentive Compensation Plan, as amended 26,188,825 7,988 505,954
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774922028414/0001437749-22-028414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.